·□□□□□·

□□□□□□□□HPV□□□□□□□□□□□□□□□□

□□[1] □□□[1] □□□[1] □□[1] □□□·□□□[1] □□□[1] □□□[2] □□[1] □□[3] □□□[1]

[1]□□□□□□/□□□□□□□□□□□□/□□□□□□□□□□□□□□□□

□□□□□□□□

□□□□□□□□ □□□□□ □□□□ □ □□□□ □ □□□□ □□□□ □ □□□□□□□□□

□□□□ □□□□□

。 HPV HPV52 58
16 HR-HPV HPV58
68 52 。
病 CIN2＋ HR-HPV 3
HPV16 52 58 。 行
。 HPV16 52 58 。

□□□□

□ □ □ □

1 de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis, 2007, 7(7): 453-459. DOI: 10.1016/S1473-3099(07)70158-5.
2 Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Prevalence of human papillomavirus in cervical intraepithelial neoplasia and invasive cervical cancer in Spain: a systematic review and meta-analysis. J Clin Virol, 2016, 77: 1-10. DOI: 10.1016/j.jcv.2016.01.009.
3 Nikolaidis C, Mehlhorn G, Hadler J, et al. Risk factors and poverty in human papillomavirus vaccination completion. Am J Prev Med, 2011, 41(4): 428-433. DOI: 10.1016/j.amepre.2011.06.032.
4 Elfström KM, Smelov V, Johansson AL, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ, 2014, 348: g130. DOI: 10.1136/bmj.g130.
5 Song H, Bai B, Zhu J, et al. Prediction of cervical cancer using human papillomavirus genotyping, cytology and clinical features among women in China. J Gynecol Oncol, 2018, 29(4): e62. DOI: 10.3802/jgo.2018.29.e62.
6 Zhao FH, Hu SY, Zhang X, et al. Type-specific human papillomavirus prevalence and distribution of cervical cancer and precancerous lesions in China: a pooled analysis of 37 case-control studies. Int J Cancer, 2017, 140(12): 2805-2815. DOI: 10.1002/ijc.30713.